Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. (2022). Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease. test, 3(1), 313-322. doi: 10.21608/ejmr.2022.222940
Mostafa M. Elkholy; Hossam H Aboubakr; Noha A. Abd ElMonem; Rasha H Soliman; Mohammed M. Masoud. "Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease". test, 3, 1, 2022, 313-322. doi: 10.21608/ejmr.2022.222940
Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. (2022). 'Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease', test, 3(1), pp. 313-322. doi: 10.21608/ejmr.2022.222940
Elkholy, M., Aboubakr, H., Abd ElMonem, N., Soliman, R., Masoud, M. Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease. test, 2022; 3(1): 313-322. doi: 10.21608/ejmr.2022.222940

Quantitative EEG Spectral Power Ratio As Cognitive Biomarker For Patients With Parkinson Disease

Egyptian Journal of Medical Research
Article 24, Volume 3, Issue 1, January 2022, Pages 313-322    PDF (370.4 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.222940
Authors
Mostafa M. Elkholy1; Hossam H Aboubakr2; Noha A. Abd ElMonem2; Rasha H Soliman2; Mohammed M. Masoud2
1Department of Clinical Neurophysiology (Neuro-Diagnostic and Research Center), Faculty of Medicine, Beni-Suef University, Egypt
2Department of Neurology, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
Background: Cognitive decline in patients with Parkinson disease (PD) is a major and progressing health problem that needs reliable and objective assessment tools. Aim: Toexplore the value of EEG spectral ratio as cognitive biomarker in patients with PD. Methods: This cross-sectional case control study enrolled 35 patients with PD and 20 matched healthy controls. All participants were evaluated by quantitative electroencephalography (EEG) spectral power ratio (slow/fast) over different head regions, in addition to clinical and neuropsychological assessment of the patients using Unified Parkinson’s Disease Rating Scale (UPDRS) and Montreal Cognitive Assessment (MoCA). Results: The UPDRS score of the patients was (mean 46.8 ± SD 26.6) and total MoCA score was (mean 20.3 ± SD 5.7). Twenty four of PD patients had cognitive impairment (MoCA <26) and showed significant higher spectral power ratio over the occipital region compared to PD patients with normal cognition (P=0.028). No significant differences of spectral power ratio between PD patients and controls. No significant correlation was found between power spectral ratio, UPDRS and MoCA scores. Conclusions: The occipital EEG spectral power ratio could be used as a complementary tool to neuropsychological assessment in evaluation and follow up of cognitive decline in patients with PD.
Keywords
Quantitative EEG; Spectral power ratio; Parkinson disease, Cognitive decline, Mild cognitive impairment
References
 

  1. Aarsland D. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. Parkinsonism & related disorders 2016;22:144-148.‏
  2. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement disorders 2012; 27(3):349-356.‏
  3. Geraedts VJ, Marinus J, Gouw AA, Mosch A, Stam CJ, van Hilten JJ, et al. Quantitative EEG reflects non-dopaminergic disease severity in Parkinson’s disease. Clinical Neurophysiology 2018;129(8):1748-1755.‏
  4. Stylianou M, Murphy N, Peraza LR, Graziadio S, Cromarty R, Killen A, et al. Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clinical Neurophysiology 2018;129(6):1209-1220.‏
  5. Hughes A, Daniel S, Kilford L, Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. JNNP 1992;55:181-184.
  6. Fahn S, Elton R. and Members of the UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn, S, Marsden CD, Calne DB, Goldstein M. Recent Developments in Parkinson’s disease, Vol. 2. Florham Park: McMellam Health Care Information 1987; P. 153-163.
  7. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4): 695–9.
  8. Rahman TA, El Gaafary MM. Montreal Cognitive Assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatrics & gerontology international 2009;9(1): 54-61.‏
  9. Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, et al. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism & related disorders 2007;13(6):348-354.‏
  10. Fonseca LC, Tedrus GM, Letro GH, Bossoni AS. Dementia, mild cognitive impairment and quantitative EEG in patients with Parkinson's disease. Clinical EEG and neuroscience 2009;40(3): 168-172.‏
  11. Dubbelink KT, Stoffers D, Deijen JB, Twisk JW, Stam CJ, Berendse HW. Cognitive decline in Parkinson's disease is associated with slowing of resting-state brain activity: a longitudinal study. Neurobiology of aging 2013;34(2): 408-418.‏
  12. Fonseca LC, Tedrus GM, Carvas PN, Machado EC. Comparison of quantitative EEG between patients with Alzheimer’s disease and those with Parkinson’s disease dementia. Clinical Neurophysiology 2013;124(10):1970-1974.‏
Statistics
Article View: 315
PDF Download: 343